Crossmark

Long-term survival, patterns of progression, and patterns of use for patients with newly diagnosed glioblastoma treated with or without Tumor Treating Fields (TTFields) in a real-world setting

Crossref DOI link: https://doi.org/10.1007/s11060-025-04946-w

Published Online: 2025-03-31

Published Print: 2025-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Riegel, Devon C.

Bureau, Britta L.

Conlon, Patrick

Chavez, Gordon

Connelly, Jennifer M.
License Information

Text and Data Mining valid from 2025-03-31

Version of Record valid from 2025-03-31
More Information

Article History

Received: 1 November 2024

Accepted: 17 January 2025

First Online: 31 March 2025

Declarations

:

: This study was performed in line with the principles of the Declaration of Helsinki. Institutional Review Board (IRB) approval was granted by the Ethics Committee of the Medical College of Wisconsin (11/11/2019, PRO00036224).

: Participant consent was waived per IRB. De-identified data was used for analysis and all participants remain de-identified in the body of the manuscript and figures.

: Authors Patrick Conlon and Gordon Chavez are current employees of Novocure Inc. Jennifer M. Connelly recently served on a Physician Advisory Panel for Novocure. Devon C. Riegel, and Britta L. Bureau declare they have no financial interests.

Document is current

Any future updates will be listed below